Show simple item record

dc.contributor.authorBuka, Richard J
dc.contributor.authorSutton, David J
dc.contributor.authorNicolson, Phillip Lr
dc.date.accessioned2024-03-28T14:58:22Z
dc.date.available2024-03-28T14:58:22Z
dc.date.issued2024-02-15
dc.identifier.citationBuka RJ, Sutton DJ, Nicolson PL. Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis. 2024 Apr;57(4):739-741. doi: 10.1007/s11239-024-02948-5. Epub 2024 Feb 15.en_US
dc.identifier.issn0929-5305
dc.identifier.eissn1573-742X
dc.identifier.doi10.1007/s11239-024-02948-5
dc.identifier.pmid38358568
dc.identifier.urihttp://hdl.handle.net/20.500.14200/4042
dc.description.abstractNo abstract availableen_US
dc.language.isoenen_US
dc.publisherKluwer Academic Publishersen_US
dc.relation.urlhttps://link.springer.com/journal/11239en_US
dc.subjectHaematologyen_US
dc.subjectCardiologyen_US
dc.subjectEmergency medicineen_US
dc.titleEnoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.en_US
dc.typeArticle
dc.source.journaltitleJournal of Thrombosis and Thrombolysis
dc.source.countryUnited Kingdom
dc.source.countryNetherlands
rioxxterms.versionNAen_US
dc.contributor.trustauthorNicolson, Phillip Lr
dc.contributor.departmentHaematologyen_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.affiliationUniversity of Birmingham; University Hospitals North Midlands NHS Trust; University Hospitals Birmingham NHS Foundation Trusten_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record